



## FDA market clearance of Ambu aScope 3

As of 5 November 2013, Ambu's single-use videoscope – aScope 3 – has received market clearance from the U.S. Food and Drug Administration (FDA) for sale in the US, which means that Ambu will launch aScope 3 in the US at the beginning of 2014. aScope 3 was launched in Europe in May 2013.

### Contact and further information

Lars Marcher, CEO  
Tel. +45 5136 2490  
E-mail: [lm@ambu.com](mailto:lm@ambu.com)

### Read more online

On the website [www.ambu.com/ascope3](http://www.ambu.com/ascope3) you can read more on aScope 3 and the clinical areas it can be used within.



aScope 3 and aView (touch screen monitor).



Intubation with aScope 3. Monitor shows the vocal cords of the patient.

### About Ambu

Since 1937, breakthrough ideas have fuelled our work on bringing efficient healthcare solutions to life. This is what we create within our fields of excellence – Anaesthesia, Patient Monitoring & Diagnostics, and Emergency Care. Millions of patients and healthcare professionals worldwide depend on the functionality and performance of our products. We are dedicated to improve patient safety and determined to advance single-use devices. The manifestations of our efforts range from early inventions like the Ambu bag and the legendary Blue Sensor® electrodes to our newest landmark solutions like the aScope™ – the world's first single-use flexible video scope. Our commitment to bring new ideas and superior service to our customers has made Ambu one of the most recognized medical companies in the world. Headquartered near Copenhagen in Denmark, Ambu employs approximately 2,200 people in Europe, North America and the Asia Pacific. For more information, please visit [www.ambu.com](http://www.ambu.com).